Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 1.425p 125,191 08:00:00
Bid Price Offer Price High Price Low Price Open Price
1.35p 1.50p 1.425p 1.425p 1.425p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.47 -0.30 -0.11 5.3

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:34:081.44125,1911,800.00O
2018-12-11 12:55:311.3560,000810.00O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
12/12/2018
08:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.43p.
Feedback Plc has a 4 week average price of 1.43p and a 12 week average price of 1.25p.
The 1 year high share price is 3.58p while the 1 year low share price is currently 1.20p.
There are currently 373,283,250 shares in issue and the average daily traded volume is 474,461 shares. The market capitalisation of Feedback Plc is £5,319,286.31.
28/11/2018
11:48
tim000: I would guess Friday. Obviously the interest will be in invoices secured in the current FY. They won't have any figures yet for Q2 FY19 (assuming results are announced this week), but they should be able to provide an update since the previous Trading Update, which covered Q1. And maybe something on Cadran. Personally I'm not expecting anything so significant that it will move the share price, I'm expecting next year to be more interesting. But you never know...
22/11/2018
15:27
tim000: To be fair this news is pretty marginal. To get the share price moving up to what we believe would be a more appropriate level, we need a succession of positive trading updates, ideally based on new sales but also any news on product developments, marketing collaborations and progress on getting FDA approval. Versarian's Neill Ricketts is a role model in that respect, and VRS's share price has risen correspondingly. (Of course VRS's graphene has a much larger prospective market than that of FDBK, although both have achieved worldwide interest.)
16/11/2018
13:30
sonie01: Peeps whats your views on this one? Good product but share price not going anywhere!!!
06/11/2018
14:01
lr2: In not quite 2 weeks since the placing, buys appear to have exceeded sells by around 30 million shares and the share price has risen around 7.5% with most of that happening today. I doubt we'll need another 30 million shares being bought to see that rise being eclipsed.
26/10/2018
20:15
goodbloke1: Any idea what the realistic share price is on FDA approval?
25/10/2018
19:43
lr2: Once you hand the FDA documentation over the FDA attempt to give you a decision within 90 days. If your documentation is faulty then you have to start again. Costs around £50k a go. Not sure if it is sensible to start down that route until TexRAD has all necessary US patents signed off. Think the share price isn't going anywhere until the placing has gone through even though the MM's are displaying all the signs of not having any shares at present. Am betting that current buyers won't be getting their shares delivered any day soon.
25/9/2018
10:23
lr2: 170k more shares bought than sold so far today and share price still down on the day. MM's want cheap shares.
12/9/2018
12:05
lr2: On a completely different matter, I have noticed that Flying Brands directors have purchased 2.2 million shares this week and the Flying Brands share price hasn't moved. There is obviously heavy selling going on in that share for 2.2 million shares to be bought and it make no difference to the price. I wonder why all this selling started this week. Lack of faith in the management perhaps.
14/6/2018
15:03
lr2: I believe the people who gained shares in the last placing are primarily the sellers now as they can likely bank a profit and load up again at the new placing price which looks an odds on certainty to be below 2p by a fair margin. I'm not at all happy with the BoD right now, they had the opportunity to issue a further 46,938,800 under the existing right to issue shares even without contemplating a rights issue to existing shareholders. No warning RNS needed so no wholesale price destruction either. The share price on the day before the General Meeting RNS was 2.8p. If they had issued then, even at a highly discounted 2.5p they would have raised £1.17 million. Let's see what gets raised next time around. The price they raise at is likely to be 1.75p at the rate this share is falling, maybe less. At 1.75p, they will need to use 67,055,430 to achieve the same result. That almost 21 million more shares for no more money. To save themselves from looking like prize pumpkins I would suggest the board will offer even more shares as a saving face exercise. If the board are active investors in this new placing then it looks just a little bit like trading on inside knowledge to me. Time will tell how close I am to being correct.
13/6/2018
10:49
lr2: Yes, but by indicating another money raising they've made it a lot harder for the share price in the short term. I don't blame the board as much as I do Trevor Brown. He decimated the share price by his pernicious selling over the previous 12 months. The board opted to raise a minimal amount at the very low price caused by Trevor Brown but they could have raised some more money (they still had the authority to do so) without calling for a special meeting. That is where, perhaps, they went wrong. Once the market was forewarned of a another likely raising lots of people sold up and pushed the share price downwards. And that is why the share price is where it is. When the clinical version of TexRAD sees light of day, that's when the share price lifts off.
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181212 13:03:06